New Delhi: On Friday, Delhi’s  All India Institute Of Medical Sciences (AIIMS) has administered the  first dose of Bharat Biotech’s ”Covaxin” to a 30-year-old male, days after the medical institute received approval from the ethics committee to start the human trials. The subject will be monitored for two weeks after which he will be given the second dose.

A total of 12 volunteers were called for number of pre-tests that include blood and nasopharyngeal testing for COVID -19. Reportedly, five volunteers would be vaccinated on Friday in the first phase of human clinical trials of the vaccine.

After the first dose trial a report of 10 selected individuals on their health condition will be submitted to the ethics committee, which will help for reviewing the entire process.

AIIMS, Delhi has received around 3,500 applications from volunteers who wanted to take part in the clinical trial process, being led by AIIMS doctor Sanjay Roy. Out of which, 100 healthy people will be vaccinated during the trial.

About 50 types of tests, including diabetes, hypertension, heart disease, kidney and liver diseases are being conducted on study participants to ensure that they are healthy and fit for the trial.

In phase I, vaccine trial will be examined on healthy people aged between 18 and 55 and on women with no pregnancy. The vaccine would be tested on 375 volunteers in the first phase. The second phase would include around 750 volunteers.